Download full text PDF

A.H. Sharaf Toxicologist, the Group of General and Specific Types of Toxicity, Institute of Experimental Pharmacology (Saint-Petersburg) E-mail: E.D. Bondareva Head of the Biosafety Group, Institute of Experimental Pharmacology (Saint-Petersburg) K.L. Kryshen Ph.D.(Biol.), Head of the Department of Toxicology and Microbiology, Institute of Experimental Pharmacology (Saint-Petersburg) O.N. Pozharitskaja Ph.D.(Pharm.), Deputy Director for New Technologies, Institute of Experimental Pharmacology (Saint-Petersburg) M.N. Makarova Dr.Sc. (Med.), Deputy Director for Science, Institute of Experimental Pharmacology (Saint-Petersburg)

The mutagenic activity of the drug based on the tridecapeptide H-Tyr-D-Arg-Phe-Gly-(D-Arg)8-Gly-OH * 10HCl was studied. The tridecapeptide is a combination of the tetrapeptide (Tyr-D-Arg-Phe-Gly-NH2) and an oligoarginine vector. The introduction of the octoarginine fragment into the structure of the tetrapeptide molecule makes it possible to increase the resistance of the peptide to proteolytic enzymes of the gastrointestinal tract, creating a per-spective of the oral administration of the drug candidate. In addition, for the octoarginine peptides, the ability to penetrate the cell through the membrane through various molecular mechanisms and to increase the permeability of the blood-brain barrier (BBB) has been established. Mutagenic properties have been studied in the mouse blood erythrocyte micronucleus test and in the Ames test. In the Ames test, it was found that the test object at concentrations of 10000.01 μg/ml had no mutagenic effect on the Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 when tested with and without metabolic activation. However, a statistically significant decrease in the number of colonies was revealed, up to their complete absence at the concentration of the investigated substance of 1000 μg/ml, which indicates the cytotoxic effect of the substance H-TYR-D-ARG-PHE-GLY-(D-ARG)8-GLY-OH * 10HCL, which could not be detected in a screening study. A metabolic activation sharply re-duces the cytotoxic properties of the test substance (in a variant of the test with metabolic activation, cytotoxic properties appear only on strain TA98). This suggests that the test object is subjected to methabolism in the liver tissue, which requires further study. The micronucleus test shows the absence of a mutagenic effect of the tridecapeptide substance in doses of 1 mg/kg and 10 mg/kg for single and seven-day intragastric administration.

oligoarginine vector
micronucleus test
Ames test

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Shabanov P.D. Farmakologija lekarstvennyh preparatov peptidnoj struktury // Psihofarmakologija i biologicheskaja narkologija. 2008. T. 8. S. 2399-2425.
  2. Solov'ev V.B. Nejropeptidy: strukturno-funktsional'-naja klassifikatsija // Actucalscience. 2015. № 4. S. 22-35.
  3. Kacprzak M.M., Peinado J.R., Than M.E., Appel J., Henrich S., Lipkind G., Houghten R.A., Bode W., Lindberg I. Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine // J Biol Chem. 2004. V. 279. № 35. R. 36788-36794.
  4. Khen Eng Ng, Mohd Cairul Iqbal Mohd Amin, corresponding author Haliza Katas, Muhammad Wahab Amjad, Adeel Masood Butt, Prashant Kesharwani, and Arun K. Iyer. pH-Responsive Triblock copolymeric micelles decorated with a cell-penetrating peptide provide efficient doxorubicin delivery // Nanoscale Res. Lett. 2016. № 11. R. 539.
  5. Yoneda A., Couchman J.R. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans // Matrix Biol. 2003. V. 22. № 1. R. 25-33.
  6. Mironov A.N. Rukovodstvo po provedeniju dokliniche-skih issledovanij lekarstvennyh sredstv. Ch. 1. M.: Grif i K. 2012.
  7. OECD (2014), Test No. 474: Mammalian Erythrocyte Micronucleus Test. OECD Publishing. Paris; doi: 10.1787/9789264224292-en.
  8. International Conference on Harmonisation; guidance on S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use; availability // Notice. Fed. Regist. 2012. V. 77. № 110. R. 33748-33749.
  9. Opisanie nabora Ames MPF 98/100/1535/1537 [Elek-tronnyj resurs]. Rezhim dostupa:
  10. Ames B.N., Mc. Cann J., Vamasaki E. Methods for detection carcinogens and mutagens with Salmonella/mammalian microsome mutagenicity test // Mutat. Res. 1975. V. 31. № 6. R. 347-364; doi: 10.1016/0165-1161(75)90046-1.
  11. Atsapkina A.A., Kryshen' K.L., Makarova M.N., Makarov V.G. Primenenie bakterial'nyh test-sistem dlja otsenki potentsial'nogo mutagennogo effekta novyh farmatsevticheskih soedinenij // Mezhdunarodnyj vestnik veterinarii. 2014. № 2. S. 109-113.
  12. Barnes W., Tuley E., Eisenstadt E. Base-sequence analysis of His+ revertants of the hisG46 missense mutation in Salmonella typhimurium // Environ. Mutagen. 1982. V. 4. № 3. R. 297-297.
  13. Ames B.N., Lee F.D., Durston W.E. An improved bacterial test system for the detection and classification of mutagens and carcinogens // Proc. Natl. Acad. Sci. USA. 1973. № 70. R. 782-786.
  14. Belitsikij G.A., Hudolej V.V. Kratkosrochnye testy v sisteme vyjavlenija kantserogennyh dlja cheloveka himicheskih soedinenij // Voprosy onkologii. 1998. T. 32. № 4. S. 1-3.
  15. Direktiva 2010/63/EU Evropejskogo parlamenta i Soveta Evropejskogo Sojuza ot 22.09.2010 g. po ohrane zhivotnyh, ispol'zuemyh v nauchnyh tseljah.
  16. Hayashi M., Morita T., Kodama Y., Sofuni T., Ishidate M. (Jr.) The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides // Mutat. Res. 1990. V. 245. № 4. R. 245-249.
  17. Oliveira-Martins C.R., Grisolia C.K. Determination of mi-cronucleus frequency by acridine orange fluorescent staining in peripheral blood reticulocytes of mice treated topically with different lubricant oils and cyclophosphamide // Genetics and Molecular Research. 2007. V. 6. № 3. R. 566-574.
  18. Thybaud V., Kasper P., Sobol Zh., Elhajouji A., Fellows M., Guerard M., Lynch A.M., Sutter A. and Tanir J.Y. Genotoxicity assessment of peptide/protein-related biotherapeutics: points to consider before testing // Mutagenesis. 2016. № 31. R. 375–384.
  19. Castellino S., de Castiglione R., Forino R., Galantino M. and Pulci R. Mutagenic contaminants in synthetic peptides obtained by an azide coupling // Mutagenesis. 1991. V. 6. № 3. R. 185-187.